Back to Search
Start Over
Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen Aα-Chain Amyloidosis
- Source :
- Journal of the American Society of Nephrology. 20:444-451
- Publication Year :
- 2009
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2009.
-
Abstract
- Mutations in the fibrinogen A alpha-chain gene are the most common cause of hereditary renal amyloidosis in the United Kingdom. Previous reports of fibrinogen A alpha-chain amyloidosis have been in isolated kindreds, usually in the context of a novel amyloidogenic mutation. Here, we describe 71 patients with fibrinogen amyloidosis, who were prospectively studied at the UK National Amyloidosis Centre. Median age at presentation was 58 yr, and renal involvement led to diagnosis in all cases. Even after a median follow-up of 4 yr, clinically significant extra-renal disease was rare. Renal histology was characteristic: striking glomerular enlargement with almost complete obliteration of the normal architecture by amyloid deposition and little or no vascular or interstitial amyloid. We discovered four amyloidogenic mutations in fibrinogen (P552H, E540V, T538K, and T525fs). A family history of renal disease was frequently absent. Median time from presentation to ESRD was 4.6 yr, and the estimated median patient survival from presentation was 15.2 yr. Among 44 patients who reached ESRD, median survival was 9.3 yr. Twelve renal transplants survived for a median of 6.0 (0-12.2) yr. Seven grafts had failed after median follow up from transplantation of 5.8 yr, including three from recurrent amyloid after 5.8, 6.0, and 7.4 yr; three grafts failed immediately for surgical reasons and one failed from transplant glomerulopathy after 5.8 yr with no histological evidence of amyloid. At censor, the longest surviving graft was 12.2 yr. In summary, fibrinogen amyloidosis is predominantly a renal disease characterized by variable penetrance, distinctive histological appearance, proteinuria, and progressive renal impairment. Survival is markedly better than observed with systemic AL amyloidosis, and outcomes with renal replacement therapy are comparable to those for age-matched individuals with nondiabetic renal disease.
- Subjects :
- Male
Nephrology
Amyloid
Pathology
medicine.medical_specialty
Time Factors
medicine.medical_treatment
urologic and male genital diseases
Renal amyloidosis
Clinical Research
Median follow-up
Internal medicine
AL amyloidosis
Humans
Medicine
Whole Body Imaging
Renal replacement therapy
Radionuclide Imaging
Aged
Family Health
business.industry
Amyloidosis
Fibrinogen
Transplant glomerulopathy
General Medicine
Middle Aged
medicine.disease
Kidney Transplantation
Pedigree
Renal Replacement Therapy
Transplantation
Treatment Outcome
Mutation
Female
business
Subjects
Details
- ISSN :
- 10466673
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Journal of the American Society of Nephrology
- Accession number :
- edsair.doi.dedup.....be937cbb354c1054b9e529998ff61478
- Full Text :
- https://doi.org/10.1681/asn.2008060614